Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors during the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advances review found that conolidine interacts Together with the atypical chemokine receptor ACKR3